Product Hub

Product hub: Rapid contamination testing for cell culture and cell-based samples

Posted: 16 February 2022 | | No comments yet

The Celsis Adapt™ unlocks advantages of utilising a single in-house RMM, achieving critical results necessary to ensure patient safety.

The need for rapid microbiological methods (RMMs) for quality control is not new. The pharmaceutical industry has made slow progress adopting them over the last decade, with a sharp spike in uptake within the last two years. To resolve new challenges caused by the COVID-19 pandemic, contend with supply chain issues and release therapies faster to patients, the industry turned toward RMMs as a solution. The industry paradigm has shifted from rapid methods being a “nice to have” option to a model in which they are critical, if not necessary, for continuous operation and the ability to release products safely.